ライフサイエンスコーパス: venous thromboembolism

1 ildren <2 years of age with catheter-related venous thromboembolism).

2 c bleeding, infection of the amniotic fluid, venous thromboembolism).

3 solve the pressing public health problem of venous thromboembolism.

4 a composite of adjudicated major arterial or venous thromboembolism.

5 ury, arrhythmia, acute coronary syndrome and venous thromboembolism.

6 ardial injury, myocarditis, arrhythmias, and venous thromboembolism.

7 reduced mobility places patients at risk for venous thromboembolism.

8 sus standard anticoagulants in children with venous thromboembolism.

9 boembolism and patients that did not develop venous thromboembolism.

10 1 patient (0.05%; 95% CI, 0.01 to 0.30) had venous thromboembolism.

11 m and major bleeding events in patients with venous thromboembolism.

12 temic cancer therapy are at varying risk for venous thromboembolism.

13 atients were followed for 3 months to detect venous thromboembolism.

14 tion of coagulation and an increased risk of venous thromboembolism.

15 ere approved for treatment and prevention of venous thromboembolism.

16 ression, asthma, chronic kidney disease, and venous thromboembolism.

17 peutic option for treatment of patients with venous thromboembolism.

18 obese patients with atrial fibrillation and venous thromboembolism.

19 ut MPN presented elevated odds for prevalent venous thromboembolism.

20 ry artery disease, ischemic stroke (IS), and venous thromboembolism.

21 s, and variables known to be associated with venous thromboembolism.

22 dications other than atrial fibrillation and venous thromboembolism.

23 hemic stroke, peripheral artery disease, and venous thromboembolism.

24 influence the occurrence of PTS or recurrent venous thromboembolism.

25 ffective strategy to reduce the incidence of venous thromboembolism.

26 TEIN-Jr phase 3 trial in children with acute venous thromboembolism.

27 the standard treatment for cancer-associated venous thromboembolism.

28 tations of standard of care in children with venous thromboembolism.

29 suggest a beneficial effect of statin use on venous thromboembolism.

30 are potentially modifiable risk factors for venous thromboembolism.

31 l-line associated bloodstream infections and venous thromboembolism.

32 , obstructive sleep apnoea, osteoporosis and venous thromboembolism.

33 can identify patients at increased risk for venous thromboembolism.

34 a, 529 patients (1.4%) developed symptomatic venous thromboembolism.

35 ildren aged birth to less than 18 years with venous thromboembolism.

36 G containing ICs may also reduce the risk of venous thromboembolism.

37 ]), which dominated the overall reduction in venous thromboembolism.

38 s standard of care in treating children with venous thromboembolism.

39 The secondary outcome was venous thromboembolisms.

40 adjusted RR was 0.58 (95% CI 0.47-0.71) for venous thromboembolism, 1.27 (0.92-1.74) for major bleed

41 All of these patients experienced venous thromboembolism: 10 patients (76.9%) had isolated

42 ), stroke (11 more cases [95% CI, 2 to 23]), venous thromboembolism (11 more cases [95% CI, 3 to 22])

43 (876 more cases [95% CI, 606 to 1168]), and venous thromboembolism (21 more cases [95% CI, 12 to 33]

44 n DNA sequence variants for association with venous thromboembolism (26,066 cases and 624,053 control

45 atherothrombosis but also for prevention of venous thromboembolism, (3) the finding that dual pathwa

46 equal to 4 days (4 points), prior history of venous thromboembolism (4 points), mechanical ventilatio

47 logical events (25%), arrhythmias (22%), and venous thromboembolism (9%).

48 [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was

49 Patients who had both venous thromboembolism and atrial fibrillation were excl

50 ted with multiple health problems, including venous thromboembolism and atrial fibrillation, both of

51 Obese patients are also at higher risk for venous thromboembolism and dialysis.

52 iological and environmental underpinnings of venous thromboembolism and its complications.

53 Differences in the risk of recurrent venous thromboembolism and major bleeding events between

54 n and rivaroxaban in prevention of recurrent venous thromboembolism and major bleeding events in pati

55 n in preventing the development of recurrent venous thromboembolism and major bleeding events.

56 ere the cumulative incidences of symptomatic venous thromboembolism and major bleeding within 3 month

57 direct oral anticoagulants in patients with venous thromboembolism and non-valvular atrial fibrillat

58 mpared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillati

59 ere compared between patients that developed venous thromboembolism and patients that did not develop

60 their mechanisms, and provides an update on venous thromboembolism and pulmonary hypertension associ

61 ic insights into the genetic epidemiology of venous thromboembolism and suggest a greater overlap amo

62 this study was to determine the frequency of venous thromboembolism and the degree of inflammatory an

63 eness outcome was the incidence of recurrent venous thromboembolism and the primary safety outcome wa

64 isms for the 50% of patients with unprovoked venous thromboembolism and to better understand mechanis

65 , with key terms relating to the population (venous thromboembolism and total knee replacement) and t

66 ombus resolution, and freedom from recurrent venous thromboembolism and venous thromboembolism-relate

67 n thrombosis in a lower limb, and death from venous thromboembolism and was assessed up to day 180.

68 ies of patients who were at elevated risk of venous thromboembolism and were randomly assigned to eit

69 agent (which might mitigate the lethality of venous thromboembolism) and those for which mortality da

70 examines the effect of heparin on survival, venous thromboembolism, and bleeding in patients with ca

71 r malignancies, major cardiovascular events, venous thromboembolism, and mortality.

72 plications, such as urinary tract infection, venous thromboembolism, and myocardial infarction, on th

73 d that risk of all outcomes in patients with venous thromboembolism, and stroke and composite bleedin

74 was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome

75 S) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetr

76 mary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat),

77 Apixaban for the treatment of venous thromboembolism associated with cancer.

78 y unknown loci, bringing the total number of venous thromboembolism-associated loci to 33, and subseq

79 efficacy outcomes were symptomatic recurrent venous thromboembolism, asymptomatic deterioration on re

80 arin for the primary outcome of incidence of venous thromboembolism at 10 to 13 days postoperatively.

81 The primary outcome was the incidence of venous thromboembolism at 3 months.

82 riptive statistics outlined the frequency of venous thromboembolism at any time during severe coronav

83 ssion, including two patients diagnosed with venous thromboembolism at presentation to the hospital.

84 These findings are consistent with venous thromboembolism being a manifestation of advanced

85 adult patients with an incident diagnosis of venous thromboembolism between January 2010 and December

86 associated with dialysis initiation and with venous thromboembolism but not with major adverse cardia

87 t effective strategy to prevent arterial and venous thromboembolism, but treating older individuals i

88 tor (older than 65 years, male sex, previous venous thromboembolism, cancer, autoimmune disease, thro

89 by independent replication with up to 17,672 venous thromboembolism cases and 167,295 controls.

90 embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients wi

91 with rosuvastatin having the lowest risk on venous thromboembolism compared with other statins 0.57

92 nrolled patients with atrial fibrillation or venous thromboembolism, compared a novel oral anticoagul

93 data for adult patients with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonar

94 assessed the association of statin use with venous thromboembolism, deep vein thrombosis, or pulmona

95 lacebo or no treatment and collected data on venous thromboembolism, deep vein thrombosis, or pulmona

96 ociated with lower use of DOACs for incident venous thromboembolism despite controlling for other cli

97 ent highlights future research priorities in venous thromboembolism, developed by experts and a crowd

98 -dimer and peak D-dimer were associated with venous thromboembolism development (p < 0.05).

99 coagulation marker elevation associated with venous thromboembolism development.

100 a degree of inflammatory marker elevation to venous thromboembolism development.

101 0 ng per milliliter, respectively), none had venous thromboembolism during follow-up (95% confidence

102 outcome was objectively confirmed recurrent venous thromboembolism during the trial period.

103 tically significant effects of prevention on venous thromboembolism endpoints.

104 The secondary objective was to compare venous thromboembolism events and coagulation variables

105 the study was to determine the prevalence of venous thromboembolism events in patients infected with

106 no difference in baseline characteristics or venous thromboembolism events.

107 t to which statins are associated with first venous thromboembolism events.

108 ths or, in children who had catheter-related venous thromboembolism for at least 6 weeks.

109 that heparin reduces the risk of symptomatic venous thromboembolism for patients with cancer; however

110 Historically, venous thromboembolism has received the greatest attenti

111 th higher scores indicating a higher risk of venous thromboembolism) has been validated to identify p

112 ore of 15-18 (2%) had a high (17.7%) risk of venous thromboembolism (hazard ratio, 28.1; 95% CI, 21.7

113 -14 (22%) had an intermediate (3.6%) risk of venous thromboembolism (hazard ratio, 6.7; 95% CI, 5.3-8

114 associated with decreased risk of recurrent venous thromboembolism (HR 0.37 [95% CI 0.24-0.55]; p<0.

115 accident (HR, 6.0; 95% CI, 2.6 to 14.1), and venous thromboembolism (HR, 24.7; 95% CI, 14.0 to 43.6).

116 owing outcomes: acute cardiac event; stroke; venous thromboembolism; hypertension; and diabetes melli

117 een shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk

118 We found no symptomatic recurrent venous thromboembolism in any patients (0%, 0.0-3.9).

119 ow-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated me

120 ic rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents.

121 Treatment of venous thromboembolism in children is based on data obta

122 this study was to determine the frequency of venous thromboembolism in critically ill coronavirus dis

123 nt study aimed to describe the prevalence of venous thromboembolism in critically ill patients receiv

124 We report a 100% occurrence of venous thromboembolism in critically ill patients suppor

125 (F5(L) ) is a common genetic risk factor for venous thromboembolism in humans.

126 edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer.

127 prophylaxis may be inadequate in preventing venous thromboembolism in severe coronavirus disease 201

128 ce of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period.

129 parin with regard to the prevention of major venous thromboembolism in these patients.

130 The primary outcome was venous thromboembolism incidence between 10 and 13 days

131 in children younger than 18 years with acute venous thromboembolism initially treated (5-21 days) wit

132 complications (acute kidney injury, sepsis, venous thromboembolism, intensive care unit admission >4

133 The reported incidence of venous thromboembolism is 1.5-3.4% of infected patients,

134 The perception that venous thromboembolism is a common cause of mortality sh

135 Venous thromboembolism is a major cause of morbidity and

136 Hospital-associated venous thromboembolism is a major patient safety concern

137 Venous thromboembolism is a significant cause of mortali

138 Venous thromboembolism is associated with increased mort

139 dental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagul

140 er who were at intermediate-to-high risk for venous thromboembolism (Khorana score, >=2) and were ini

141 Major arterial or venous thromboembolism, major adverse cardiovascular eve

142 Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mo

143 Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse eve

144 tive international registry of patients with venous thromboembolism (March 2001-January 2019), we exp

145 gure), consistent with the increased rate of venous thromboembolism observed in patients with sickle

146 ckle clots may explain the increased risk of venous thromboembolism observed in SCD.

147 Clinically diagnosed symptomatic venous thromboembolism occurred in 1.4% of this large po

148 Venous thromboembolism occurred in 10 of the 719 patient

149 Venous thromboembolism occurred in 12 of 288 patients (4

150 Recurrent venous thromboembolism occurred in 32 of 576 patients (5

151 Major venous thromboembolism occurred in 4 of 1661 patients (0

152 Recurrent venous thromboembolism occurred in 41 patients (12-month

153 Venous thromboembolism occurred in 5 of the 731 patients

154 iod of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 chil

155 verse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in p

156 Prespecified subgroup analysis of venous thromboembolism occurrence by cancer type identif

157 ulant administration on all-cause mortality, venous thromboembolism occurrence, and bleeding related

158 , 0.505; 95% CI, 0.336-0.759; p = 0.001) and venous thromboembolism (odds ratio, 0.569; 95% CI, 0.330

159 urgery who were considered to be at risk for venous thromboembolism on the basis of the investigator'

160 pixaban, rivaroxaban, or warfarin for either venous thromboembolism or atrial fibrillation between Ma

161 ysis that examined significant predictors of venous thromboembolism or central-line associated bloods

162 result in a significantly lower incidence of venous thromboembolism or death due to venous thromboemb

163 primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 m

164 , 1.07-1.27]), but inversely associated with venous thromboembolism (OR, 0.79 [95% CI, 0.67-0.93]) an

165 ure (OR, 1.00 [95% CI, 0.68-1.47]; P=0.996), venous thromboembolism (OR, 1.04 [95% CI, 0.77-1.39]; P=

166 site of major bleeding, INR of 4 or greater, venous thromboembolism, or death.

167 risk of major bleeding, INR of 4 or greater, venous thromboembolism, or death.

168 orted associations between statins and first venous thromboembolism outcomes were identified from MED

169 in 1.5% versus 0.5% ( P=0.32), and recurrent venous thromboembolism over 24 months was observed in 13

170 efficacy outcome was objectively documented venous thromboembolism over a follow-up period of 180 da

171 Previous venous thromboembolism (p=0.014), being bedbound in the

172 ors with DOAC use among commercially insured venous thromboembolism patients.

173 An increased rate of venous thromboembolism (peripherally inserted central ca

174 alysis established that the causal effect of venous thromboembolism prevention on mortality was null

175 ld be revised considering the null effect of venous thromboembolism prevention on mortality.

176 We used data from venous thromboembolism prevention trials to evaluate the

177 ive APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration

178 ndomised controlled trials (RCTs) evaluating venous thromboembolism prevention.

179 o question the use of composite endpoints in venous thromboembolism-prevention trials and provide rat

180 included children with objectively confirmed venous thromboembolism previously treated with low-molec

181 Routine chemical venous thromboembolism prophylaxis may be inadequate in

182 o assess the relative efficacy and safety of venous thromboembolism prophylaxis strategies and to pop

183 ients received routine subcutaneous chemical venous thromboembolism prophylaxis.

184 Venous thromboembolism (pulmonary embolism or any lower-

185 emic attack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operativ

186 tion trials to evaluate the causal effect of venous thromboembolism reduction on mortality.

187 deep-vein thrombosis, pulmonary embolism, or venous thromboembolism-related death during the treatmen

188 om from recurrent venous thromboembolism and venous thromboembolism-related death.

189 Although many patients with venous thromboembolism require extended treatment, it is

190 were positive, with significantly increased venous thromboembolism risk in patients in control group

191 of the population at an equivalent incident venous thromboembolism risk to carriers of the establish

192 Venous thromboembolism risk was elevated in survivors of

193 The ICU-Venous Thromboembolism score can identify patients at in

194 The ICU-Venous Thromboembolism score consists of six independent

195 A prediction score (the ICU-Venous Thromboembolism score) was derived from independe

196 Randomisation was stratified by age and venous thromboembolism site.

197 Outcomes of recurrent venous thromboembolism, stroke, and bleeding were measur

198 Increased risks of venous thromboembolism [summary estimate (SE), 95% confi

199 al-line associated bloodstream infection and venous thromboembolism than central venous catheters in

200 py resulted in a significantly lower rate of venous thromboembolism than did placebo among intermedia

201 loped a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the populat

202 366 patients prescribed an anticoagulant for venous thromboembolism, the incidence of recurrent venou

203 (76% of the sample) had a low (0.3%) risk of venous thromboembolism; those with a score of 9-14 (22%)

204 se results indicate that platelet APP limits venous thromboembolism through a negative regulation of

205 ing risk for stroke, pulmonary embolism, and venous thromboembolism through its effect on thrombin-in

206 hase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily riva

207 In children with acute venous thromboembolism, treatment with rivaroxaban resul

208 e rate of stent occlusion (patency loss) and venous thromboembolism varies substantially across indic

209 primary outcome was the 3-month incidence of venous thromboembolism (VTE) after a MRDTI negative for

210 ne the risk factors for 30-day postdischarge venous thromboembolism (VTE) after bariatric surgery and

211 ely stratify risk or provide prophylaxis for venous thromboembolism (VTE) among surgical patients.

212 cer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events.

213 There may be many predictors of venous thromboembolism (VTE) and bleeding in hospitalize

214 Early reports describe high venous thromboembolism (VTE) and disseminated intravascu

215 WAS) have confirmed known risk mutations for venous thromboembolism (VTE) and identified a number of

216 y contribute to thrombotic diseases, such as venous thromboembolism (VTE) and ischemic stroke.

217 T) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may increase expos

218 Genetic predispositions to venous thromboembolism (VTE) are relatively frequent in

219 The increased risk of venous thromboembolism (VTE) associated with pregnancy i

220 failure to provide defect-free postoperative venous thromboembolism (VTE) chemoprophylaxis, (2) ident

221 to 2 pregnant women in 1000 will experience venous thromboembolism (VTE) during pregnancy or postpar

222 The annual number of US venous thromboembolism (VTE) events, the number of poten

223 The incidence of pediatric venous thromboembolism (VTE) has been increasing signifi

224 se 2019 (COVID-19) with an increased risk of venous thromboembolism (VTE) has resulted in specific gu

225 r for predicting initial, but not recurrent, venous thromboembolism (VTE) in cancer, a setting in whi

226 n thromboprophylaxis (EDT) for prevention of venous thromboembolism (VTE) in medical patients remain

227 rmed a meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with esse

228 ernational normalized ratio (INR) to prevent venous thromboembolism (VTE) in warfarin-treated patient

229 Venous thromboembolism (VTE) incidence in children has s

230 Venous thromboembolism (VTE) is a major preventable dise

231 Venous thromboembolism (VTE) is a significant contributo

232 Venous thromboembolism (VTE) is a significant public hea

233 Venous thromboembolism (VTE) is associated with signific

234 Venous thromboembolism (VTE) is common in patients with

235 rtant decision in the long-term treatment of venous thromboembolism (VTE) is how long to anticoagulat

236 Venous thromboembolism (VTE) is rare in healthy children

237 nship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain.

238 agulation in patients with cancer-associated venous thromboembolism (VTE) is unknown.

239 is associated with the highest incidence of venous thromboembolism (VTE) of any cancer type.

240 ening for cancer in patients with unprovoked venous thromboembolism (VTE) often is considered, but cl

241 ated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention.

242 Heparin administration for venous thromboembolism (VTE) prophylaxis in patients wit

243 superior to unfractionated heparin (UH) for venous thromboembolism (VTE) prophylaxis in patients wit

244 However, the association between GDF-15 and venous thromboembolism (VTE) remains uncertain.

245 All patients with venous thromboembolism (VTE) should receive anticoagulan

246 al patients individually risk stratified for venous thromboembolism (VTE) using Caprini scores.

247 role of the polymorphism at position 310 in venous thromboembolism (VTE) using the International Net

248 e, no study has assessed whether the risk of venous thromboembolism (VTE) varies with blunt or penetr

249 alignancy are at 4- to 7-fold higher risk of venous thromboembolism (VTE), a potentially fatal, yet p

250 pulmonary embolism, collectively defined as venous thromboembolism (VTE), are the third leading caus

251 h immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from

252 nt option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported

253 Venous thromboembolism (VTE), caused by altered hemostas

254 Venous thromboembolism (VTE), composed of pulmonary embo

255 For patients with venous thromboembolism (VTE), prediction of bleeding is

256 Risk factors for venous thromboembolism (VTE), such as older age, maligna

257 ias in a substantial number of patients with venous thromboembolism (VTE), the initial hope that thei

258 Venous thromboembolism (VTE), which includes both deep v

259 Venous thromboembolism (VTE), which includes deep vein t

260 Venous thromboembolism (VTE), which includes deep vein t

261 pulmonary embolism are collectively known as venous thromboembolism (VTE), which is a common vascular

262 es patients at increased short-term risk for venous thromboembolism (VTE).

263 al patients with additional risk factors for venous thromboembolism (VTE).

264 what extent HF confers an increased risk of venous thromboembolism (VTE).

265 ) formation in carriers without a history of venous thromboembolism (VTE).

266 eminated intravascular coagulation (DIC) and venous thromboembolism (VTE).

267 herosclerosis may be associated with risk of venous thromboembolism (VTE).

268 nal cardiovascular disease risk factors with venous thromboembolism (VTE).

269 , stroke, and transient ischemic attack) and venous thromboembolism (VTE).

270 dentify ENTPD1 polymorphisms associated with venous thromboembolism (VTE).

271 Cancer patients have an increased risk of venous thromboembolism (VTE).

272 s) regarding serious adverse events, such as venous thromboembolism (VTE).

273 eminated intravascular coagulation (DIC) and venous thromboembolism (VTE).

274 r peripheral artery disease (PAD) events and venous thromboembolism (VTE).

275 In RCTs, the RR for venous thromboembolism was 0.85 (0.73-0.99; p=0.038) whe

276 The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegment

277 The primary efficacy outcome of major venous thromboembolism was a composite of symptomatic di

278 Symptomatic venous thromboembolism was defined as deep vein thrombos

279 Venous thromboembolism was diagnosed in 31 patients (28%

280 hemic cerebrovascular accident (4% each) and venous thromboembolism was low (0% vs 13%, P = 0.23).

281 The rate of recurrent venous thromboembolism was lower but the rate of major b

282 received prophylactic anticoagulant therapy; venous thromboembolism was not clinically suspected ante

283 thrombosis in 7 of 12 patients (58%) in whom venous thromboembolism was not suspected before death; p

284 thromboembolism, the incidence of recurrent venous thromboembolism was similar between the apixaban,

285 The crude incidence of recurrent venous thromboembolism was three per 100 person-years in

286 th higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients w

287 Annualized rates of stent occlusion or venous thromboembolism were 7.8 (acute thrombotic), 15.0

288 HRs for heart failure or cardiomyopathy and venous thromboembolism were greater in patients without

289 rdiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive car

290 al-line associated bloodstream infection and venous thromboembolism were included.

291 All complications except venous thromboembolism were significantly reduced in the

292 th complicated recoveries (death, infection, venous thromboembolism) were matched with 12 cases with

293 een suggested to have a protective effect on venous thromboembolism (which includes deep vein thrombo

294 with active cancer have an increased risk of venous thromboembolism, which results in substantial mor

295 pitals in 28 countries with documented acute venous thromboembolism who had started heparinisation we

296 ods for diagnosing, treating, and preventing venous thromboembolism will allow tailoring of diagnosti

297 D-dimer greater than 2,600 ng/mL predicted venous thromboembolism with an area under the receiver o

298 false-negative rate (defined as diagnosis of venous thromboembolism within 90 d).

299 parin for the treatment of cancer-associated venous thromboembolism without an increased risk of majo

300 Low-molecular-weight heparin reduces risk of venous thromboembolism without increasing risk of major